Tuesday, April 09, 2013 1:42:53 PM
I am re-posting a some other poster's week old message. Worth the read in times like this.
Read this like morning prayer until next PR
THE FACTS ARE: READ..
Timeline
4-30-2012: Regen BioPharma, a subsidiary of BMSN, is formed.
5-8-2012: J. Christopher Mizer hired as President and COO.
6-6-2012: David White MD, Wei-Ping Min MD/PHD, and Vald Bogin MD are appointed as members of the Scientific Advisory Board.
6-7-2012: Granted access to patent for stimulating blood cell production with stem cells.
6-15-2012: David Audley joins the advisory board.
6-26-2012: Thomas E. Ichim PhD joins as Chief Scientific Officer and Director of Research.
10-29-2012: BMSN participates in the 2012 Stem Cell Meeting on the Mesa. There, J. Christopher Mizer explains their business plan. Check it out!
11-19-2012: Pre-Clinical study for HemaXellerate begins.
1-24-2013: Peer-Reviewed Publication Provides Preclinical Support for HemaXellerate.
2-5-2013: Investigational New Drug (IND) Application is filed with the FDA for HemaXellerate.
2-26-2013: A Letter of Intent (LOI) is entered into to purchase a patent for a gene silencing treatment for breast cancer.
3-12-2013: BMSN settles an old lawsuit it had.
3-18-2013: Receives the IND # from the FDA for HemaXellerate.
3-22-2013: All SEC financials are brought up-to-date and BMSN is up-listed from the Pinks to the OTC-QB.
Where we're at now
BE PATIENT…I doubt all this effort just to be a scam.
Read this like morning prayer until next PR
THE FACTS ARE: READ..
Timeline
4-30-2012: Regen BioPharma, a subsidiary of BMSN, is formed.
5-8-2012: J. Christopher Mizer hired as President and COO.
6-6-2012: David White MD, Wei-Ping Min MD/PHD, and Vald Bogin MD are appointed as members of the Scientific Advisory Board.
6-7-2012: Granted access to patent for stimulating blood cell production with stem cells.
6-15-2012: David Audley joins the advisory board.
6-26-2012: Thomas E. Ichim PhD joins as Chief Scientific Officer and Director of Research.
10-29-2012: BMSN participates in the 2012 Stem Cell Meeting on the Mesa. There, J. Christopher Mizer explains their business plan. Check it out!
11-19-2012: Pre-Clinical study for HemaXellerate begins.
1-24-2013: Peer-Reviewed Publication Provides Preclinical Support for HemaXellerate.
2-5-2013: Investigational New Drug (IND) Application is filed with the FDA for HemaXellerate.
2-26-2013: A Letter of Intent (LOI) is entered into to purchase a patent for a gene silencing treatment for breast cancer.
3-12-2013: BMSN settles an old lawsuit it had.
3-18-2013: Receives the IND # from the FDA for HemaXellerate.
3-22-2013: All SEC financials are brought up-to-date and BMSN is up-listed from the Pinks to the OTC-QB.
Where we're at now
BE PATIENT…I doubt all this effort just to be a scam.
Join the InvestorsHub Community
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
